Differences in Clinical Responses to Ustekinumab Treatment among Body Regions: Results from a Real-World Prospective, Observational, and Multi-Center Study in Korea-Reference-Cited by-同舟云学术

Differences in Clinical Responses to Ustekinumab Treatment among Body Regions: Results from a Real-World Prospective, Observational, and Multi-Center Study in Korea

Published:2022 Issue:1 Volume:34 Page:14
ISSN:1013-9087
Container-title:Annals of Dermatology
language:en
Short-container-title:Ann Dermatol

Author:

Son Sang Wook¹^ORCID,Yu Dae Young²³^ORCID,Kim Youngdoe³^ORCID,Ahn Hyo Hyun⁴^ORCID,Jang Yong Hyun⁵^ORCID,Roh Joo Young⁶^ORCID,Lee Young Bok⁷^ORCID,Lee Ji Yeoun⁸^ORCID,Kim Myung Hwa⁹^ORCID,Lee YoungJa³^ORCID,Park Gyeong-Hun¹⁰^ORCID,Yoon Hyun-Sun¹¹^ORCID,Youn Sang Woong¹²^ORCID,

Affiliation:

1. Department of Dermatology, Korea University Ansan Hospital, Ansan, Korea.

2. Department of Public Health, Korea University College of Medicine, Seoul, Korea.

3. Medical Affairs, Janssen Korea, Seoul, Korea.

4. Department of Dermatology, Korea University Anam Hospital, Seoul, Korea.

5. Department of Dermatology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.

6. Department of Dermatology, Gachon University Gil Medical Center, Incheon, Korea.

7. Department of Dermatology, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Korea.

8. Department of Dermatology, Chungbuk National University Hospital, Cheongju, Korea.

9. Department of Dermatology, Dankook University Hospital, Cheonan, Korea.

10. Department of Dermatology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.

11. Department of Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea.

12. Department of Dermatology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

Funder

Janssen Korea Ltd

Publisher

Korean Dermatological Association and The Korean Society for Investigative Dermatology

Subject

Dermatology

Link

https://anndermatol.org/pdf/10.5021/ad.2022.34.1.14

Reference16 articles.

1. The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPI-PSODE)

2. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

3. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

4. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response

5. Severe Psoriasis – Oral Therapy with a New Retinoid

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors Associated With Achieving Complete Skin Clearance Compared to Almost Complete Skin Clearance in Patients With Moderate to Severe Psoriasis Treated With Biologics: A Retrospective Chart Review;Annals of Dermatology;2024

2. Basic Therapeutic Approach for Patients with Plaque Psoriasis: Korean Expert Consensus Using the Modified Delphi Method;Annals of Dermatology;2023

3. Variation of body regional responses to Ustekinumab and Secukinumab in psoriasis patients: A real‐world retrospective study and literature review;Dermatologic Therapy;2022-11-22